MURs (Medicine Use Reviews)
New MUR target requirements from 1st October 2019
New targeting requirements apply to Medicines Use Review (MURs) conducted from 1st October 2019, so community pharmacy contractors will need to update their standard operating procedure for the service to reflect these changes. These changes were agreed as part of the five-year Community Pharmacy Contractual Framework agreement.
Seventy percent of MURs conducted from 1st October 2019 to 31st March 2020 must be within the following two target groups:
- patients taking high-risk medicines; or
- patients recently discharged from hospital who had changes made to their medicines while they were in hospital.Between 1st April 2019 and 31st March 2020, contractors can undertake up to 250 MURs per pharmacy, but no more than 200 may be undertaken between 1st April 2019 and 30th September 2019.
- From 1st October 2019, patients with respiratory disease and patients at risk of or diagnosed with cardiovascular disease and regularly being prescribed at least four medicines are no longer target groups for MURs.
The underlying purpose of an MUR service is, with the patient’s agreement, to improve the patient’s knowledge and use of medication. In particular, this should aim to:
- Establish patients’ actual use, understanding and experience of taking medicine
- Identify, discuss and resolve poor or ineffective use of medicines by the patient
- Identify side effects or drug interactions that may affect the patient’s compliance with how the health care professional would like them to use the medicine; and
- Improve the clinical and cost effectiveness of medicines prescribed to patients and thereby reduce medicine wastage.
- Chronic Obstructive Pulmonary Disease (COPD) Consultation Toolkit
- MURs by telephone or away from premises – decision crib sheet
- To view the Psoriasis MUR Toolkit click